Aparna Narayanan is a Reporter at Investor’s Business Daily. She covers a range of topics including finance, trading, and energy, with a particular focus on nuclear energy, renewable energy, and energy policy and regulation. Aparna's insights and reporting have been featured in Investor's Business Daily, Outlook Publishing (India) Pvt. Ltd., Yahoo News, and Yahoo Finance.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Aparna's coverage focuses on investment analysis within various industries, including automotive, sales & marketing, and gaming. She would likely be interested in receiving pitches from financial analysts or industry experts who can provide valuable insights into the stock market trends, AI technology, and specific companies mentioned in her articles.
Given Aparna's focus on citing data and investment analysis across a variety of sectors such as automotive and gaming, she may appreciate pitches that offer unique quantitative analyses or forecasts based on reliable market data.
As there is no specified geographic focus for Aparna's articles, she appears to take a broad international view of investment opportunities. Therefore, relevant sources with global perspectives could effectively reach out to her.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Aparna Narayanan
Chevron earnings more than tripled in second quarter, the Dow Jones energy giant reported early Friday, easily beating high expectations. Exxon Mobile also is on tap. The Big Oil stocks rose slightly before the open, near buy points.
By: Aparna Narayanan
Chevron earnings more than tripled, easily beating views for the Dow Jones energy giant. Exxon Mobil earnings soared but fell short.
By: Aparna Narayanan
Guardant Health is Thursday's IBD Stock Of The Day in a thriving market for colon cancer screening tests. On Friday, Guardant Health stock surged after the company raised full-year outlook after a Q2 revenue beat late Thursday. Several analysts raised price targets on GH stock after the Q2 report, by as much as $50 a share, according to TheFly.
By: Aparna Narayanan
Weight loss drug stock leaders slumped on Friday amid updates and ahead of earnings. NVO stock sank under a buy point on trial results. LLY stock dived below support with earnings due next week. Updating the closely watched ZEUS phase 3 clinical trial, Denmark's Novo Nordisk announced overnight that its experimental cardiovascular drug, ziltivekimab — to treat heart disease, kidney disease and inflammation — failed in the late-stage trial.
By: Aparna Narayanan
Novo Nordisk and Eli Lilly, the firms behind Ozemic, Wegovy and Zepbound, faced selling pressure on Friday.
By: Aparna Narayanan
Chevron earnings more than tripled, easily beating views for the Dow Jones energy giant. Exxon Mobil earnings soared but fell short.
By: Aparna Narayanan
Novo Nordisk and Eli Lilly, the firms behind Ozemic, Wegovy and Zepbound, faced selling pressure on Friday.
By: Aparna Narayanan
Forum Energy staged a powerful earnings breakout, with several others due.
By: Aparna Narayanan
Small-cap oil stock Forum Energy Technologies broke out on Monday after blowout second-quarter earnings. Most oil stocks fell with crude prices, though many of them are eyeing buy points in a busy week of earnings for the oil and gas sector.
By: Aparna Narayanan
Five energy names reporting this week may double or triple earnings per share. One small-cap stock broke out.
